1
|
Hitoto H, Crochette N, Ménager P, Blanchi S, Lainé J, Grandière-Perez L, Paris A, Berrehare A, Scholastique F, Goupil F. REPERCOV : repérage des plaintes fonctionnelles et psychosociales après une hospitalisation pour infection sévère à SARS-CoV-2. Med Mal Infect 2020. [PMCID: PMC7441946 DOI: 10.1016/j.medmal.2020.06.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Introduction Dans le contexte d’une des pandémies les plus meurtrières du 21e siècle, la France, au 15 juin 2020, comptait plus de 73 000 personnes sorties d’hospitalisation après infection par le nouveau Coronavirus (SARS-CoV-2). Les symptômes et signes cliniques de la COVID-19 sont variés, comme la fièvre, les troubles respiratoires, signes ORL ou encore digestifs. Il semblerait que certains patients se plaignent de la persistance de ces symptômes longtemps après l’infection. Nous avons souhaité évaluer, à distance d’une hospitalisation, la prévalence des signes fonctionnels, des plaintes psychologiques et sociales justifiant d’une prise en charge spécifique chez les patients hospitalisés pour infection sévère à SARS-CoV-2. L’objectif final était de recenser les besoins pour offrir un suivi adapté à cette pathologie émergente. Matériels et méthodes Nous avons réalisé une enquête auprès des 200 à 300 patients survivants hospitalisés entre le 1er mars et le 30 juin 2020 pour infection sévère à SARS-COV-2, au sein de notre établissement. Un questionnaire papier ou une enquête téléphonique étaient proposés deux à trois mois après la sortie d’hospitalisation afin de recueillir les plaintes existant avant et après l’infection. Il s’agissait d’une étude purement descriptive, portant sur un ensemble de signes fonctionnels présents avant ou après l’infection, qu’ils soient cardiorespiratoires, digestifs, ORL, locomoteurs, neurologiques, mais aussi sur les traitements concomitants. Des questionnaires validés abordaient les dimensions de la qualité de vie, de la fragilité, notamment en population gériatrique. Résultats Outre la prévalence des plaintes présentes 2–3 mois après la sortie d’hospitalisation, nous nous sommes intéressés à : – décrire les plaintes fonctionnelles, neuropsychologiques et sociales à distance d’une infection sévère à SARS-CoV-2, et l’évolution de celles-ci avant, pendant et après l’hospitalisation ; – repérer les facteurs favorisants de ces plaintes, en particulier les facteurs de risques usuels (mode de vie, habitus, comorbidités, traitements, modalités de prise en charge, etc.) ; – décrire les besoins en consultations spécialisées et en accompagnement neuropsychologique, en suivi diététique ou suivi social ; – décrire l’impact de la COVID-19 sur la prise en charge de la maladie chronique de certains patients, notamment la prise en charge thérapeutique ; – décrire les facteurs d’inégalités d’accès au soin et étudier leur impact sur la gravité de l’infection et la présence d’une plainte fonctionnelle ou psychosociale. Conclusion Cette nouvelle maladie soulève de nombreuses questions, notamment sur les éventuelles séquelles sanitaires qu’elle engendre. La parole des survivants est donc capitale pour décrire les signes fonctionnels et les plaintes psychosociales, nécessitant une prise en charge spécifique, coordonnée, afin de pouvoir améliorer le pronostic à long terme des patients infectés par le SARS-CoV-2 et créer un parcours de soins optimal.
Collapse
|
2
|
Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel TA, Lescure FX, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky JM, Michel M, Perrodeau E, Carlier N, Roche N, de Lastours V, Ourghanlian C, Kerneis S, Ménager P, Mouthon L, Audureau E, Ravaud P, Godeau B, Gallien S, Costedoat-Chalumeau N. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020; 369:m1844. [PMID: 32409486 PMCID: PMC7221472 DOI: 10.1136/bmj.m1844] [Citation(s) in RCA: 268] [Impact Index Per Article: 67.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/05/2020] [Indexed: 12/27/2022]
Abstract
OBJECTIVE To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. DESIGN Comparative observational study using data collected from routine care. SETTING Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March 2020. PARTICIPANTS 181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care. INTERVENTIONS Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group). MAIN OUTCOME MEASURES The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress syndrome, weaning from oxygen, and discharge from hospital to home or rehabilitation (all at day 21). Analyses were adjusted for confounding factors by inverse probability of treatment weighting. RESULTS In the main analysis, 84 patients who received hydroxychloroquine within 48 hours of admission to hospital (treatment group) were compared with 89 patients who did not receive hydroxychloroquine (control group). Eight additional patients received hydroxychloroquine more than 48 hours after admission. In the weighted analyses, the survival rate without transfer to the intensive care unit at day 21 was 76% in the treatment group and 75% in the control group (weighted hazard ratio 0.9, 95% confidence interval 0.4 to 2.1). Overall survival at day 21 was 89% in the treatment group and 91% in the control group (1.2, 0.4 to 3.3). Survival without acute respiratory distress syndrome at day 21 was 69% in the treatment group compared with 74% in the control group (1.3, 0.7 to 2.6). At day 21, 82% of patients in the treatment group had been weaned from oxygen compared with 76% in the control group (weighted risk ratio 1.1, 95% confidence interval 0.9 to 1.3). Eight patients in the treatment group (10%) experienced electrocardiographic modifications that required discontinuation of treatment. CONCLUSIONS Hydroxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies. However, the results of this study do not support its use in patients admitted to hospital with covid-19 who require oxygen.
Collapse
Affiliation(s)
- Matthieu Mahévas
- Department of Internal Medicine, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Viet-Thi Tran
- Centre for Clinical Epidemiology, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Centre of Research in Epidemiology and Statistics, Paris, France
| | - Mathilde Roumier
- Department of Internal Medicine, Foch Hospital, Suresnes, France
| | - Amélie Chabrol
- Department of Infectious Diseases, Sud Francilien Hospital, Corbeil-Essonnes, France
| | - Romain Paule
- Department of Internal Medicine, Foch Hospital, Suresnes, France
| | - Constance Guillaud
- Department of Internal Medicine, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Elena Fois
- Department of Internal Medicine, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Raphael Lepeule
- Transversal Infections Treatment Unit, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France
| | - Tali-Anne Szwebel
- Department of Internal Medicine, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | | | - Frédéric Schlemmer
- Pulmonology Unit, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France
| | - Marie Matignon
- Department of Nephrology, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France
| | - Mehdi Khellaf
- Department of Internal Medicine, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Etienne Crickx
- Department of Internal Medicine, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Benjamin Terrier
- Department of Internal Medicine, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Caroline Morbieu
- Department of Internal Medicine, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Paul Legendre
- Department of Internal Medicine, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Julien Dang
- Centre for Clinical Epidemiology, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Centre of Research in Epidemiology and Statistics, Paris, France
| | - Yoland Schoindre
- Department of Internal Medicine, Foch Hospital, Suresnes, France
| | - Jean-Michel Pawlotsky
- Department of Virology, Bacteriology-Hygiene, and Mycology-Parasitology Centre, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marc Michel
- Department of Internal Medicine, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Elodie Perrodeau
- Centre for Clinical Epidemiology, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Centre of Research in Epidemiology and Statistics, Paris, France
| | - Nicolas Carlier
- Department of Pulmonology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Nicolas Roche
- Department of Pulmonology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Victoire de Lastours
- Department of Internal Medicine, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Clément Ourghanlian
- Pharmacy, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France
| | - Solen Kerneis
- Mobile Infectious Disease Team, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Philippe Ménager
- Pulmonology Unit, Sud Francilien Hospital, Corbeil-Essonnes, France
| | - Luc Mouthon
- Department of Internal Medicine, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Etienne Audureau
- Clinical Epidemiology and Aging Team, Mondor Institute for Biomedical Research (INSERM U955), Public Health Services, Henri-Mondor Hosptial, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France
| | - Philippe Ravaud
- Centre for Clinical Epidemiology, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Centre of Research in Epidemiology and Statistics, Paris, France
| | - Bertrand Godeau
- Department of Internal Medicine, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France
| | - Sébastien Gallien
- Department of Infectious Diseases, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Pari, Paris-Est Créteil University, Créteil, France
| | - Nathalie Costedoat-Chalumeau
- Centre for Clinical Epidemiology, Hôtel-Dieu Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Centre of Research in Epidemiology and Statistics, Paris, France
- Department of Internal Medicine, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| |
Collapse
|
4
|
Eschwège P, Paradis V, Conti M, Holstege A, Richet F, Detève J, Ménager P, Legrand A, Jardin A, Bedossa P, Benoit G. In situ detection of lipid peroxidation by-products as markers of renal ischemia injuries in rat kidneys. J Urol 1999; 162:553-7. [PMID: 10411087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
PURPOSE Lipid peroxidation is an autocatalytic mechanism leading to oxidative destruction of cellular membranes. In renal transplantation, this mechanism is triggered by ischemia/reperfusion and may be of relevance in graft failure. MATERIALS AND METHODS Using specific antibodies directed against malondialdehyde (MDA) and 4-hydroxynonenal (HNE) adducts, major aldehydic metabolites of lipid peroxidation, we investigated, in situ, by means of an immunohistochemical procedure, the occurrence of lipid peroxidation during different warm ischemic periods of 0, 15, 30, 45 and 60 minutes in rat kidneys prior to reperfusion. The same experiments included followup of the rats after nephrectomy and reperfusion for 10 days. RESULTS We observed superficial and deep cortex immunostaining with both antibodies against MDA and HNE after 30 minutes of warm ischemia. This immunostaining was observed in the absence of any histological lesions, as assessed by routine staining. After 45 and 60 minutes of warm ischemia, lipid peroxidation byproducts were detected both in the cortex and in the medulla, which is associated with 33% and 66% of rat deaths respectively. CONCLUSIONS This study confirms the involvement of the lipid peroxidation process in kidney damage during anoxia before reperfusion, and its extension to the whole organ. Lipid peroxidation byproducts were detectable in warm ischemic kidney, and the presence of medulla immunostaining was associated with the animals' death. Lipid peroxidation immunostaining might thus be useful as a sensitive tool to detect ischemic damage after warm ischemia prior to reperfusion, as well as in the decision to carry out kidney transplantation in humans.
Collapse
Affiliation(s)
- P Eschwège
- Laboratoire de Chirurgie Expérimentale, Faculté de Médecine Paris-Sud, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|